Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint

Results from an Amgen trial showing that anemia therapy Aranesp has a neutral impact on survival in cancer patients receiving chemotherapy could assuage concerns over the safety profile of erythropoiesis-stimulating agents at high doses